Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

October 18, 2021 POWER 25 HEALTHCARE

2021 Power 25 Health Care: Trevor MacDougall, Alexander Zinke and Paul Sanders

The leadership team at Lumeda consists of, left to right, Trevor MacDougall, founder; Alexander Zinke, CEO, and Paul Sanders, founder.

Connecticut’s biotech industry predominantly resides in New Haven but Greater Hartford also has a few players.

One is Rocky Hill-based Lumeda, which is developing a lung cancer-killing light therapy.

Leading the startup are Trevor MacDougall (co-founder), Alexander Zinke (CEO) and Paul Sanders (co-founder).

Lumeda’s photodynamic therapy technology, which was developed and licensed from oncologists at Buffalo’s Roswell Park Comprehensive Cancer Center, is an optical device that automates the targeting and dosage of laser light to the site of a newly-removed thoracic tumor. That light interacts with a drug called Photofrin that’s injected into the patient ahead of surgery and ultimately kills cancerous cells.

Improving the health of tissue adjacent to a tumor is key to reducing the rate of cancer recurrence.

The startup has some momentum, having raised $5.3 million as of April.

Sanders and MacDougall have a long history together across multiple companies and roles.

The two first crossed paths working at 3M in West Haven. In the mid-1990s, they switched jobs together and went to Wallingford-based CiDRA’s optical-sensing division, where they became steeped in monitoring technology for oil wells, and first crossed paths with Alan Kersey, a CiDRA executive and entrepreneur who nearly 20 years later would help seed Lumeda as a partner with Branford venture capital firm Cycle Venture Partners.

The co-founders brought in Zinke, a veteran of business development and commercialization projects in health care, as CEO.


Sign up for Enews


Order a PDF